IOV-001 / Imvax - LARVOL DELTA

Personalized immunotherapeutic platform with evidence of clinical activity in glioblastoma (IGV-001) protects mice against other lethal solid tumor challenges (AACR 2022) - "BDC containing saline or 1x106 IMV-001-treated tumor cells (hereon IOV-001 and IHV-001, respectively) were implanted in flanks of C57BL/6 mice and explanted 48 h later, as per glioblastoma clinical protocol. These data support the antitumor activity of this novel immunotherapeutic platform in multiple cancers beyond glioblastoma. Results suggest that efficacy is associated with a systemic immunological response, resulting in generation of Th1 antitumor cytotoxic T cells. Future studies are seeking to resolve the factors triggering good v. poor responses using phenotypic evaluation of T cell activation/exhaustion markers and Th1/Th2 cytokine production."

IO biomarker • Preclinical • Brain Cancer • Gastrointestinal Cancer • Glioblastoma • Hepatocellular Cancer • Oncology • Ovarian Cancer • Solid Tumor • CD4 • CD8 • HAVCR2 • IFNG • PD-1

Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at AACR Annual Meeting 2022 (Businesswire) - "At the meeting, Imvax will present data that support the applicability of its platform to solid tumor types beyond glioblastoma. Using murine models of hepatocellular carcinoma and ovarian cancer, Imvax found that treatment with IHV-001 hepatocellular and IOV-001 ovarian immunotherapeutic products led to a significant improvement in survival and reduction in tumor burden of mice treated."

Preclinical • Glioblastoma • Oncology • Solid Tumor